Andrew Cittadine - 29 May 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Kim R Tsuchimoto, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
29 May 2024
Net transactions value
+$23,051
Form type
4
Filing time
31 May 2024, 16:56:08 UTC
Previous filing
24 May 2024
Next filing
05 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Purchase $7,643 +12,000 +21% $0.6369 69,624 29 May 2024 Direct F1
transaction MNPR Common Stock Purchase $7,676 +12,000 +17% $0.6397 81,624 30 May 2024 Direct F2
transaction MNPR Common Stock Purchase $7,732 +12,000 +15% $0.6443 93,624 31 May 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.637, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.64, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.61 to $0.6502, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.